- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02792179
Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
October 30, 2017 updated by: Hoffmann-La Roche
A Pilot Longitudinal Follow-Up Study of Tau Burden in The Brain of Subjects With Alzheimer's Disease Who Previously Participated in Study BP29409 Using [18F]RO6958948 Positron Emission Tomography
This is a longitudinal, follow-up study in participants with Alzheimer's disease (AD) who previously participated in study BP29409 (NCT02187627).
This study is designed to assess the longitudinal change of Tau pathology in the brain of participants with AD using the PET ligand [18F]RO6958948 and to assess the safety and tolerability of PET ligand.
Study Overview
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287-0807
- Johns Hopkins Medical Institutions, Johns Hopkins Outpatient Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- AD participants previously scanned with [18F]RO6958948 in Roche Study BP29409
- Agreement to use highly effective contraception measures
- Body mass index (BMI) between 18 and 32 Kilograms per square meter (kg/m^2)
- A study partner able to accompany the participant to all visits and answer questions about the participant
- In the opinion of investigator, based on the medical history and physical examination, can safely tolerate tracer administration and the scanning procedures
- Documented positive visual read (as per local procedures for florbetapir or similar procedures for other amyloid tracers) of an amyloid PET scan, which in the opinion of the principal investigator is consistent with a diagnosis of AD
Exclusion Criteria:
Exclusion Criteria for All Participants
- History or presence of any clinically relevant hematological, hepatic, respiratory, cardiovascular, renal, metabolic, endocrine, or central nervous system disease or other medical conditions that are not well controlled, may put the participant at risk, could interfere with the objectives of the study, or make the participant unsuitable for participation in the study for any other reason in the opinion of the principal investigator
- Clinically relevant pathological findings in physical examination, electrocardiogram, or laboratory values at the screening assessment that could impact participant safety
- Known history of clinically significant infectious disease including autoimmune deficiency syndrome (AIDS) or serological indication of acute/chronic hepatitis B or C or Human Immuno Virus infection
- Women of childbearing potential must not be pregnant, or nursing and serum human chorionic gonadotropin (HCG) must be negative at the time of Screening Visit 1, and urine HCG must be negative on all subsequent visits
- Loss or donation of more than 450 milliliters (mL) blood in the 4 months before screening or donation of plasma within 14 days of screening
- Unsuitable veins for repeated venipuncture
- History of drug or alcohol abuse or positive result from urine screen for drugs of abuse
- Have received an investigational medication within the last 3 months or 5 times the elimination half-life, whichever is longer, prior to enrollment Exclusion Criteria Related to Trial Procedures
- Has had or is planning to have exposure to ionizing radiation that in combination with the study-related tracer administrations and scanning procedures would result in a cumulative exposure that exceeds the recommended annual exposure limit
- Presence of pacemakers; aneurysm clips; artificial heart valves; ear implants; foreign metal objects in the eyes, skin, or body, or any other circumstance that would contraindicate a magnetic resonance imaging (MRI) scan
- History of, or suffers from, claustrophobia or feels that he or she will be unable to lie still on their back in the MRI or PET scanner
- Has received treatment that targeted amyloid-beta or tau within the last 24 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [18F]RO6958948
Each participant will receive a single intravenous (IV) dose of [18F]RO6958948 and a single PET scan approximately 9-24 months after the baseline scan (in Study BP29409).
|
Radiolabeled low molecular weight compound, administered as single IV injection.
The mass dose of [18F]RO6958948 injected will be less than or equal to (
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Regional Standardized Uptake Value (SUV), as Assessed by the tau PET Brain Scan
Time Frame: Day 1
|
Day 1
|
Regional Standardized Uptake Value Ratios (SUVR), as Assessed by the Tau PET Brain Scan
Time Frame: Day 1
|
Day 1
|
Change in SUV for Different Brain Regions
Time Frame: Baseline to approximately 24 months
|
Baseline to approximately 24 months
|
Change in SUVR for Different Brain Regions
Time Frame: Baseline to approximately 24 months
|
Baseline to approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants with Adverse Events
Time Frame: Screening to 7-14 days after Tau PET scan (Up to approximately 7 weeks)
|
Screening to 7-14 days after Tau PET scan (Up to approximately 7 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 19, 2016
Primary Completion (Actual)
September 28, 2016
Study Completion (Actual)
September 28, 2016
Study Registration Dates
First Submitted
June 2, 2016
First Submitted That Met QC Criteria
June 2, 2016
First Posted (Estimate)
June 7, 2016
Study Record Updates
Last Update Posted (Actual)
November 1, 2017
Last Update Submitted That Met QC Criteria
October 30, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BP39126
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on [18F]RO6958948
-
Hoffmann-La RocheCompletedAlzheimer's Disease, Healthy VolunteerUnited States
-
Barcelonabeta Brain Research Center, Pasqual Maragall...Hoffmann-La Roche; Hospital Clinic of BarcelonaEnrolling by invitationHealthy | Mild Cognitive ImpairmentSpain
-
Butler HospitalEli Lilly and Company; GE Healthcare; Hoffmann-La Roche; Brown University; University... and other collaboratorsRecruitingDementia | Alzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Skane University HospitalLund UniversityRecruitingAlzheimer Disease | Mild Cognitive Impairment | Mild DementiaSweden
-
Skane University HospitalLund UniversityRecruitingParkinson Disease | Dementia | Alzheimer Disease | Frontotemporal Degeneration | Mild Cognitive Impairment | Lewy Body Disease | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Semantic Dementia | Parkinson-Dementia Syndrome | Progressive Nonfluent AphasiaSweden
-
Genentech, Inc.Completed
-
Adam BrickmanNational Institute on Aging (NIA)Completed
-
Chang Gung Memorial HospitalRecruitingProgressive Supranuclear PalsyTaiwan
-
Five Eleven Pharma, Inc.CompletedParkinson DiseaseUnited States
-
Genentech, Inc.Completed